Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.650
-0.041 (-5.92%)
At close: Apr 28, 2026, 4:00 PM EDT
0.661
+0.011 (1.69%)
After-hours: Apr 28, 2026, 6:27 PM EDT
Citius Pharmaceuticals Employees
Citius Pharmaceuticals had 23 employees as of September 30, 2025. The number of employees did not change compared to the previous year.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$171,483
Profits / Employee
-$1,560,280
Market Cap
14.55M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| IN8bio | 17 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| Soligenix | 14 |
| Genenta Science | 9 |
| Phio Pharmaceuticals | 6 |
| Pasithea Therapeutics | 5 |
| Cadrenal Therapeutics | 4 |
CTXR News
- 4 days ago - Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 4 days ago - What's Behind The Drop In Citius Pharmaceuticals? - Benzinga
- 4 days ago - Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PRNewsWire
- 5 weeks ago - Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - PRNewsWire
- 7 weeks ago - Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PRNewsWire
- 7 weeks ago - Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - PRNewsWire
- 2 months ago - Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PRNewsWire